10 Sep Lakewood-Amedex to Present Data on Bisphosphocin™ Nu-3 Bacteriacidal Effect on Bacteria Established in Biofilm at the ICAAC Conference
SARASOTA, Fla., Sept. 10, 2013 /PRNewswire/ — Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that in vitro studies demonstrate that its bisphosphocin class of antimicrobials is highly effective at killing bacteria established in biofilm. The results will be presented in a poster entitled “Novel Bisphosphocin™ Nu-3 Demonstrates Rapid Killing of Bacteria Encased in Biofilm In Vitro” on Friday, Sept 13th at the 53rd annual ICAAC Meeting from 8:30-10:30am. The studies, conducted in collaboration with Dr. Donna Akiyoshi of the Cummings School of Veterinary Medicine at Tufts University, North Grafton, Mass., expand on previously published and announced results highlighting the unique bisphosphocin mechanism of action and ability to kill highly resistant bacterial strains carrying the NDM-1 plasmid.
Paul DiTullio, Vice President Product Development, remarked, “This is a major breakthrough in antimicrobial development because the activity demonstrated by Nu-3 clearly distinguishes the bisphosphocin™ class from any other classes of antibiotics. In addition, the rapid killing rate and novel mechanism of action will make it impossible for bacteria to become resistant or evade killing through the formation of biofilm.”
Lakewood-Amedex will release additional information pertaining to these studies in the near future.
Bisphosphocins are new class of broad spectrum antimicrobial with a unique mechanism of action that results in rapid bacterial cell death. There is currently no known mechanism of resistance to the bisphosphocin class which have been proven effective in vitro against over 70 strains of bacteria including, gram positive, gram negative, NDM-1 carrying, and an array of antibiotic resistant strains. Bisphosphocins have demonstrated efficacy in preclinical models of lung, burn wound, and surgical infections and are being developed to treat a number of serious bacterial infections. The two lead compounds, designated Nu-2 and Nu-3 are being developed in topical and intravenous formulation to treat acute bacterial skin and skin structure infections, infected diabetic ulcers, ventilated assisted pneumonia, and chronic and complicated urinary tract infections.
About Lakewood-Amedex, Inc.
Lakewood-Amedex is a privately held biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds, orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, cancer, influenza, and hepatitis, and a fully human monoclonal antibody for HUS. The Company’s products and technology are covered by an extensive patent portfolio consisting of 40 granted and/or issued patents and 25 pending patent applications filed on a worldwide basis covering all major pharmaceutical markets. The Company’s lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram-positive, gram-negative, and antibiotic-resistant bacteria and is expected to enter the clinic in Q1 2014.
This press release contains forward-looking statements that can be identified by terminology such as “expects”, “potential”, “suggests”, “may”, “will” or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are “forward-looking statements” that involve risk and uncertainties, which could cause the Company’s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company’s planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.